Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Engelhardt

Showing results (161-170 of 217) with videos related to

Pageof 22
Sort By:
BMC Immunology|March 4, 2014
Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel diseaseNatalie Frede, Erik-Oliver Glocker, Jennifer Wanders, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1994
Discordant adaptation of human peritoneal macrophages to stimulation by lipopolysaccharide and the synthetic lipid A analogue SDZ MRL 953. Down-regulation of TNF-alpha and IL-6 is paralleled by an up-regulation of IL-1 beta and granulocyte colony-stimulating factor expressionH P Knopf, F Otto, R Engelhardt, et al.
American Journal of Hematology|April 15, 1999
Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometryR Fischer, C D Tiemann, R Engelhardt, et al.
Arthritis Research & Therapy|December 6, 2012
An update on the hyper-IgE syndromesPatrick F K Yong, Alexandra F Freeman, Karin R Engelhardt, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 1996
Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancerF Otto, P Schmid, A Mackensen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancerS Fetscher, W Brugger, R Engelhardt, et al.
Neurology & Clinical Neurophysiology : NCN|July 14, 2005
Interaction of artificial metallic objects with biosusceptometric measurementsR Engelhardt, E B Fung, P Kelly, et al.
Progress in Clinical and Biological Research|January 1, 1982
Experience with diathermia-induced whole-body hyperthermiaH Neumann, H A Fabricius, P Burmeister, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1985
Cell surface lectins of transplantable human teratocarcinoma cells: purification of a new mannan-specific endogenous lectinH J Gabius, R Engelhardt, J Casper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancerS Fetscher, W Brugger, R Engelhardt, et al.
Pageof 22

Showing results (161-170 of 217) with videos related to

Sort By:
Pageof 22
BMC Immunology|March 4, 2014
Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel diseaseNatalie Frede, Erik-Oliver Glocker, Jennifer Wanders, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1994
Discordant adaptation of human peritoneal macrophages to stimulation by lipopolysaccharide and the synthetic lipid A analogue SDZ MRL 953. Down-regulation of TNF-alpha and IL-6 is paralleled by an up-regulation of IL-1 beta and granulocyte colony-stimulating factor expressionH P Knopf, F Otto, R Engelhardt, et al.
American Journal of Hematology|April 15, 1999
Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometryR Fischer, C D Tiemann, R Engelhardt, et al.
Arthritis Research & Therapy|December 6, 2012
An update on the hyper-IgE syndromesPatrick F K Yong, Alexandra F Freeman, Karin R Engelhardt, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 1996
Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancerF Otto, P Schmid, A Mackensen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancerS Fetscher, W Brugger, R Engelhardt, et al.
Neurology & Clinical Neurophysiology : NCN|July 14, 2005
Interaction of artificial metallic objects with biosusceptometric measurementsR Engelhardt, E B Fung, P Kelly, et al.
Progress in Clinical and Biological Research|January 1, 1982
Experience with diathermia-induced whole-body hyperthermiaH Neumann, H A Fabricius, P Burmeister, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1985
Cell surface lectins of transplantable human teratocarcinoma cells: purification of a new mannan-specific endogenous lectinH J Gabius, R Engelhardt, J Casper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancerS Fetscher, W Brugger, R Engelhardt, et al.
Pageof 22